ClinicalTrials.gg
Active, not recruitingNCT06592794Nova 301Updated May 13, 2026

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

A Phase 3 interventional study of mRNA-1403 and Placebo in Acute Gastroenteritis and Norovirus Acute Gastroenteritis, sponsored by ModernaTX, Inc.. Active, not recruiting at 283 sites in 7 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
37,864
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 58 studies in Gastroenteritis with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Gastroenteritis · United States.

Enrollment
Largest of 50
37,864 · median 87
Started
2024
with 1 other
Phase 3
16 of 58
none open now
Registered
56th of 58
by date
Lead sponsor
2 of 58
ModernaTX, Inc.

Among the 58 studies in Gastroenteritis with a site in United States, this one has the largest enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2024, is one of 16 in phase 3, and was the 56th registered.

Gastroenteritis

237 studies on the registry are indexed under Gastroenteritis; 16 are open to participants now.

Browse Gastroenteritis studies →

Open to participants now

5 of the 58 studies in Gastroenteritis with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Gastroenteritis studies recruiting now, 5 (38%) set no upper age limit and 8 (62%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Gastroenteritis with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.

03

Conditions studied

  • Acute Gastroenteritis
  • Norovirus Acute Gastroenteritis

Browse trials for

Keywords

  • Acute Gastroenteritis
  • Norovirus Acute Gastroenteritis
  • mRNA-1403
  • Viral Gastroenteritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who understand and are willing and physically able to comply with protocol mandated follow-up, including all procedures as assessed by the Investigator, and who are primarily responsible for their self-care and activities of daily living.
  2. Participants may have chronic medical diagnoses but should be medically stable as assessed by the following criteria:

    • Absence of medical events associated with underlying diagnoses and qualifying as SAEs within 1 month prior to study intervention on Day 1.
    • Absence of known, current, and life-limiting diagnoses, which could continue for the duration of the study and which, in the opinion of the Investigator, would make completion of the protocol unlikely.
  3. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  4. Participants assigned female at birth are eligible to participate if they are not pregnant or breastfeeding/chestfeeding/bodyfeeding and meet protocol defined criteria.

Exclusion criteria

Exclusion Criteria:

  1. Participant is acutely ill or febrile (temperature ≥38.0 degrees Celsius (°C) [100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1.
  2. History of AGE within 14 days prior to Day 1 or close contact with an individual with AGE symptoms (in the home, socially, or occupationally) within 14 days prior to Day 1.
  3. History of a diagnosis or condition that in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
  4. Current diagnosis of chronic gastrointestinal (GI) disease that is associated with ongoing symptoms of regular vomiting and/or diarrhea. Participants with stable, well-controlled chronic GI disease without regular vomiting and/or diarrhea can be considered for enrollment.
  5. Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
  6. Has undergone surgical procedures within 7 days prior to Day 1 or is scheduled to undergo a surgical procedure within 28 days after study intervention.
  7. Reported history of congenital or acquired immunodeficiency, immunocompromising/ condition, asplenia, or recurrent severe infections per protocol.
  8. Reported history of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine or intervention that includes one or more of the same components contained in the study vaccine.
  9. History of myocarditis, pericarditis, or myopericarditis with onset within 180 days prior to Day 1 whose values have not returned to Baseline clinical status.
  10. History of Guillain-Barré syndrome.
  11. Reported history of coagulopathy or bleeding disorder considered a to IM injection or phlebotomy.
  12. Dermatologic conditions that could affect local solicited AR assessments.
  13. Diagnosis of within the previous 2 years (excluding nonmelanoma skin cancer).
  14. Has received systemic immunosuppressive therapies for >14 days in total within 6 months prior to Day 1 (for ≥10 milligrams (mg)/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
  15. Has received or plans to receive any licensed vaccine ≤28 days prior to or within 28 days after study intervention (Day 1), except for influenza vaccines, which may be given 14 days before or after receipt of a study intervention.
  16. Receipt of systemic immunoglobulins or blood products within 3 months prior to Day 1 or plans for receipt during the study.
  17. Has donated ≥450 mL of blood products within 28 days prior to Day 1 Visit or plans to donate blood products during the study.
  18. Participated in a clinical study with treatment within 90 days prior to Day 1 (Baseline) based on the medical history interview or plans to do so while participating in this study. Participants may continue in prior interventional study follow-up activities, provided that it does not involve further investigational treatment and/or procedures that may affect safety and/or other study endpoints, and study participation does not result in a breach of either study protocol.
  19. Is working as, has worked as, or is an immediate family member or household member of study personnel, Sponsor personnel, or study site staff directly involved with the conduct of the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
37,864 participants (actual)

Study arms

  • Experimental
    mRNA-1403

    Participants will receive a single injection of mRNA-1403 on Day 1.

    Biological: mRNA-1403

  • Placebo comparator
    Placebo

    Participants will receive a single injection of mRNA-1403 matching placebo (0.9% sodium chloride solution) on Day 1.

    Biological: Placebo

Interventions

  • BiologicalmRNA-1403

    Intramuscular (IM) injection.

  • BiologicalPlacebo

    0.9% sodium chloride solution by IM injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Day 1 up to Day 7 (7 days after study intervention)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Day 1 up to Day 28 (28 days after study intervention)

  3. Number of Participants with Medically Attended Adverse Events (MAAEs)

    Time frame: Day 1 through Day 181

  4. Number of Participants with Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), and AEs Leading to Study Withdrawal

    Time frame: Day 1 up to Day 546

  5. Vaccine Efficacy (VE) of mRNA-1403 to Prevent First Occurrence of Protocol-defined Moderate or Severe AGE Associated with Vaccine Matched Genotypes

    Time frame: Day 15 up to 9 months after last participant dosed

Secondary outcomes

  1. VE of mRNA-1403 to Prevent First Occurrence of Protocol-defined Severe AGE Associated with Vaccine Matched Genotypes

    Time frame: Day 15 up to 9 months after last participant dosed

  2. VE of mRNA-1403 to Prevent First Occurrence of Protocol-defined Severe Norovirus (NoV) AGE Associated with Any Genogroup I or II Norovirus (NoV) Genotype

    Time frame: Day 15 up to 9 months after last participant dosed

  3. VE of mRNA-1403 to Prevent First Occurrence of Protocol-defined Moderate or Severe AGE Associated with Any Genogroup I or II NoV Genotype

    Time frame: Day 15 up to 9 months after last participant dosed

  4. VE of mRNA-1403 to Prevent First Occurrence of Protocol-defined AGE of Any Severity Associated with Vaccine Matched NoV Genotypes

    Time frame: Day 15 up to 9 months after last participant dosed

  5. VE of mRNA-1403 to Prevent Any Occurrence of Medically Attended AGE Associated with Vaccine Matched NoV Genotypes, as well as any Genogroup I or II NoV Genotype

    Time frame: Day 15 up to Day 546

  6. VE of mRNA-1403 to Prevent Any Occurrence of AGE Hospitalizations Associated With Vaccine Matched NoV Genotypes, as well as any Genogroup I or II NoV Genotype

    Time frame: Day 15 up to Day 546

  7. VE of mRNA-1403 to Prevent Any Occurrence of Protocol-defined Moderate or Severe AGE Associated with Vaccine Matched Genotypes

    Time frame: Day 15 up to Day 546

  8. VE of mRNA-1403 to Prevent Any Occurrence of Protocol-defined AGE of Any Severity Associated with Any Genogroup I or II NoV Genotype

    Time frame: Day 15 up to Day 546

  9. Geometric Mean Titer (GMT) of Histo-blood Group Antigen (HBGA)-blocking Antibodies Titers Against Vaccine Matched Genotypes

    Time frame: Day 1 and Day 29

  10. Geometric Mean Fold Rise (GMFR) of HBGA-blocking Antibodies Titers Against Vaccine Matched Genotypes

    Time frame: Day 1 and Day 29

  11. Percentage of Participants with Seroresponse Based on HBGA-blocking Antibody Titer

    Time frame: Day 29

  12. GMT of Binding Antibody (bAb) Against Vaccine-matched NoV Genotypes

    Time frame: Day 1 and Day 29

  13. GMFR of bAb Titers

    Time frame: Day 1 and Day 29

  14. Percentage of Participants with Seroresponse Based on bAb Titer

    Time frame: Day 29

  15. VE of mRNA-1403 to Prevent First Occurrence of Protocol-Defined Moderate or Severe AGE Associated with Vaccine-Matched NoV Genotypes Up to 12 Months

    Time frame: Day 15 up to 12 months postdose

  16. VE of mRNA-1403 to Prevent First Occurrence of Protocol-Defined Moderate or Severe AGE Associated with Vaccine-Matched NoV Genotypes Up to 18 Months

    Time frame: Day 15 up to 18 months postdose

07

Study locations

283 sites

Showing the first 100 of 283 sites across 7 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Feb 2027, 28 months after the start.

Of 21 industry-sponsored phase 3 interventional studies under Gastroenteritis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 28 months is above that.

Counting every sponsor, half of 25 studies reached it within 19 months; a quarter within 11 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2024
First posted
Sep 19, 2024
StartActual
Sep 24, 2024
Primary completionEst.
Feb 15, 2027
CompletionEst.
Feb 15, 2027
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06592794
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 24, 2024
Primary completion
Feb 15, 2027 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
May 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion